Coralie M. Backlund

Coralie M. Backlund

Auto-generated profile, based on publicly available information

Coralie M. Backlund

Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2022 in Nature Materials
Verified
Journal Article
Open access
PDF file
EDEric L. Dane
Eric L. Dane
ABAlexis Belessiotis-Richards
Alexis Belessiotis-Richards
CBCoralie Backlund
Coralie Backlund
JWJianing Wang
Jianing Wang
KHKousuke Hidaka
Kousuke Hidaka
DIDarrell J. Irvine
Darrell J. Irvine
Activation of the innate immune STimulator of INterferon Genes (STING) pathway potentiates antitumour immunity, but systemic delivery of STING agonists to tumours is challenging. We conjugated STING-activating cyclic dinucleotides (CDNs) to PEGylated lipids (CDN-PEG-lipids; PEG, polyethylene glycol) via a cleavable linker and incorporated them into lipid nanodiscs (LNDs), which are discoid nanoparticles formed by self-assembly. Compared to state-of-the-art liposomes, intravenously administered LNDs carrying CDN-PEG-lipid (LND-CDNs) exhibited more efficient penetration of tumours, exposing the majority of tumour cells to STING agonist. A single dose of LND-CDNs induced rejection of established tumours, coincident with immune memory against tumour rechallenge. Although CDNs were not directly tumoricidal, LND-CDN uptake by cancer cells correlated with robust T-cell activation by promoting CDN and tumour antigen co-localization in dendritic cells. LNDs thus appear promising as a vehicle for robust delivery of compounds throughout solid tumours, which can be exploited for enhanced immunotherapy.

30 September 2021 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
PWPeter M. K. Westcott
Peter M. K. Westcott
NSNathan J. Sacks
Nathan J. Sacks
JSJason M. Schenkel
Jason M. Schenkel
ZEZackery A. Ely
Zackery A. Ely
OSOlivia Smith
Olivia Smith
TJTyler Jacks
Tyler Jacks

1 August 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
CBCoralie M. Backlund
Coralie M. Backlund
RHRebecca L. Holden
Rebecca L. Holden
KMKelly D. Moynihan
Kelly D. Moynihan
DGDaniel Garafola
Daniel Garafola
CFCharlotte Farquhar
Charlotte Farquhar
DIDarrell J. Irvine
Darrell J. Irvine
Peptide-based cancer vaccines are widely investigated in the clinic but exhibit modest immunogenicity. One approach that has been explored to enhance peptide vaccine potency is covalent conjugation of antigens with cell-penetrating peptides (CPPs), linear cationic and amphiphilic peptide sequences designed to promote intracellular delivery of associated cargos. Antigen-CPPs have been reported to exhibit enhanced immunogenicity compared to free peptides, but their mechanisms of action in vivo are poorly understood. We tested eight previously described CPPs conjugated to antigens from multiple syngeneic murine tumor models and found that linkage to CPPs enhanced peptide vaccine potency in vivo by as much as 25-fold. Linkage of antigens to CPPs did not impact dendritic cell activation but did promote uptake of linked antigens by dendritic cells both in vitro and in vivo. However, T cell priming in vivo requiredBatf3-dependent dendritic cells, suggesting that antigens delivered by CPP peptides were predominantly presented via the process of cross-presentation and not through CPP-mediated cytosolic delivery of peptide to the classical MHC class I antigen processing pathway. Unexpectedly, we observed that many CPPs significantly enhanced antigen accumulation in draining lymph nodes. This effect was associated with the ability of CPPs to bind to lymph-trafficking lipoproteins and protection of CPP-antigens from proteolytic degradation in serum. These two effects resulted in prolonged presentation of CPP-peptides in draining lymph nodes, leading to robust T cell priming and expansion. Thus, CPPs can act through multiple unappreciated mechanisms to enhance T cell priming that can be exploited for cancer vaccines with enhanced potency.

1 May 2017 in Journal of Controlled Release
Verified
Journal Article
Closed access
FSFederica Sgolastra
Federica Sgolastra
CBCoralie M. Backlund
Coralie M. Backlund
EOE. Ilker Ozay
E. Ilker Ozay
BDBrittany M. Deronde
Brittany M. Deronde
LMLisa M. Minter
Lisa M. Minter
GTGregory Tew
Gregory Tew

28 March 2017 in Chemistry – A European Journal
Verified
Journal Article
Closed access
PDF file
JSJoel M. Sarapas
Joel M. Sarapas
CBCoralie M. Backlund
Coralie M. Backlund
BDBrittany M. Deronde
Brittany M. Deronde
LMLisa M. Minter
Lisa M. Minter
GTGregory Tew
Gregory Tew

27 February 2017 in Biomacromolecules
Verified
Journal Article
Closed access
ATA. Özgül Tezgel
A. Özgül Tezgel
PJPaejonette Jacobs
Paejonette Jacobs
CBCoralie M. Backlund
Coralie M. Backlund
JTJanice C. Telfer
Janice C. Telfer
GTGregory Tew
Gregory Tew